NCT02696642View on ClinicalTrials.gov

Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

54

Participants

Timeline

Start Date

April 14, 2016

Primary Completion Date

July 31, 2018

Study Completion Date

August 19, 2019

Conditions

Neoplasms

Interventions

DRUG

Anetumab ravtansine (BAY94-9343)

All subjects received anetumab ravtansine 6.5 mg/kg BW (body weight) once every three weeks

Trial Locations (8)

2025

Chisinau

13385

Marseille

14073

Caen

21079

Dijon

31059

Toulouse

44805

Saint-Herblain

59020

Lille

69008

Lyon

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY